Omeprazole
- Generic Name
- Omeprazole
- Brand Names
- Konvomep, Losec, Omeclamox, Omesec, Previdolrx Analgesic Pak, Prilosec, Talicia, Yosprala, Zegerid, Zegerid Reformulated Aug 2006, Zegerid With Magnesium Hydroxide
- Drug Type
- Small Molecule
- Chemical Formula
- C17H19N3O3S
- CAS Number
- 73590-58-6
- Unique Ingredient Identifier
- KG60484QX9
- Background
Originally approved by the FDA in 1989, omeprazole is a proton-pump inhibitor, used to treat gastric acid-related disorders. These disorders may include gastroesophageal reflux disease (GERD), peptic ulcer disease, and other diseases characterized by the oversecretion of gastric acid. This drug was the first clinical useful drug in its class, and its approva...
- Indication
Omeprazole, according to the FDA label is a proton pump inhibitor (PPI) used for the following purposes:
• Treatment of active duodenal ulcer in adults
• Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer
recurrence in adults
• Treatment of active benign gastric ulcer in adults
...
- Associated Conditions
- Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Helicobacter Pylori Infection, Osteoarthritis (OA), Rheumatoid Arthritis, Upper GI Bleeding, Zollinger-Ellison Syndrome, Benign, active Gastric Ulcer, Develop NSAID-induced gastric ulcers, Hypersecretory conditions, Multiple endocrine adenomas
- Associated Therapies
- -
A Study to Evaluate the Impact of Lactobacillus Rhamnosus GG on Proton Pump Inhibitor-Induced Gut Dysbiosis
- Conditions
- Interventions
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 30
- Registration Number
- NCT05517928
- Locations
- 🇺🇸
Mayo Clinic Arizona, Scottsdale, Arizona, United States
A Study to Evaluate the Impact of Omeprazole on the Pharmacokinetics of Sotorasib Co-administered With an Acidic Beverage in Healthy Volunteers
- First Posted Date
- 2022-08-11
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Amgen
- Target Recruit Count
- 16
- Registration Number
- NCT05497557
- Locations
- 🇺🇸
Labcorp Clinical Research Unit Inc., Dallas, Texas, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05487235
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇵🇱Uniwersytecki Szpital Kliniczny w Poznaniu, Pozna?, Poland
🇪🇸NEXT Oncology-Hospital Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
A Study of Effect of Food and a Proton Pump Inhibitor on Selpercatinib (LY3527723) in Healthy Participants
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2022-07-21
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 19
- Registration Number
- NCT05468164
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
A Study of Imlunestrant (LY3484356) in Female Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2022-07-06
- Last Posted Date
- 2022-11-25
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 113
- Registration Number
- NCT05444556
- Locations
- 🇺🇸
Altasciences Clinical Los Angeles, Inc, Cypress, California, United States
🇺🇸Qps-Mra, Llc, South Miami, Florida, United States
🇺🇸ICON Early Phase Services, San Antonio, Texas, United States
Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers
- Conditions
- Interventions
- First Posted Date
- 2022-06-29
- Last Posted Date
- 2023-01-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 59
- Registration Number
- NCT05438303
- Locations
- 🇺🇸
Research Site, Berlin, New Jersey, United States
High Dose Dual Therapy vs Clarithromycin Triple Therapy for Treatment Naive H Pylori Infection in an Urban Population
- Conditions
- Interventions
- First Posted Date
- 2022-04-22
- Last Posted Date
- 2023-02-01
- Lead Sponsor
- Icahn School of Medicine at Mount Sinai
- Target Recruit Count
- 112
- Registration Number
- NCT05342532
- Locations
- 🇺🇸
Mount Sinai Union Square Division of Digestive Diseases, New York, New York, United States
Study of H2 Antagonist and a Proton Pump Inhibitor of Selpercatinib in Healthy Participants
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2024-10-30
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 20
- Registration Number
- NCT05338502
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study of ALXN1840 (Coated and Non-coated) Administered With And Without Omeprazole In Healthy Adults
- Conditions
- Interventions
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-02
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319912
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
A Study of ALXN1840 (Non-coated) Administered With And Without Omeprazole In Healthy Adults
- First Posted Date
- 2022-04-08
- Last Posted Date
- 2023-08-01
- Lead Sponsor
- Alexion Pharmaceuticals, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05319899
- Locations
- 🇺🇸
Clinical Trial Site, Lincoln, Nebraska, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.